Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
ESPR on Nasdaq
Shares outstanding
207,440,936
Price per share
$3.70
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
108,004,285
Total reported value
$286,206,908
% of total 13F portfolios
0%
Share change
+9,509,355
Value change
+$32,005,545
Number of holders
188
Price from insider filings
$3.70
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Two Seas Capital LP 4.7% -6% $25,836,769 -$543,915 9,749,724 -2.1% Two Seas Capital LP 30 Sep 2025
BB BIOTECH AG 4.9% -2% $8,821,598 -$227,500 9,694,064 -2.5% BB Biotech AG 04 Mar 2025
WASATCH ADVISORS LP 3.5% -33% $18,713,921 -$10,253,910 7,061,857 -35% Wasatch Advisors LP 30 Sep 2025

As of 30 Sep 2025, 188 institutional investors reported holding 108,004,285 shares of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR). This represents 52% of the company’s total 207,440,936 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) together control 45% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 7.2% 14,833,791 +0.82% 0% $39,309,546
VANGUARD GROUP INC 5.8% 12,092,449 +3.2% 0% $32,044,990
Two Seas Capital LP 4.7% 9,749,724 -2.1% 1.6% $25,836,769
WASATCH ADVISORS LP 3.4% 7,061,857 -32% 0.1% $18,713,921
PenderFund Capital Management Ltd. 3.2% 6,676,519 0% 3% $17,692,775
GEODE CAPITAL MANAGEMENT, LLC 2.3% 4,751,396 +3.7% 0% $12,593,578
STATE STREET CORP 2.2% 4,478,834 +19% 0% $11,868,910
MORGAN STANLEY 2% 4,055,626 +284% 0% $10,747,409
Nuveen, LLC 1.8% 3,711,069 +778% 0% $9,834,333
AIGH Capital Management LLC 1.4% 3,000,000 2.8% $7,950,000
MARSHALL WACE, LLP 1.2% 2,521,439 -53% 0.01% $6,681,814
ROYCE & ASSOCIATES LP 1.1% 2,293,488 0.06% $6,077,743
TWO SIGMA INVESTMENTS, LP 1.1% 2,238,618 +22% 0.01% $5,932,338
JANE STREET GROUP, LLC 0.94% 1,953,058 +223% 0.01% $5,175,604
TWO SIGMA ADVISERS, LP 0.92% 1,908,000 -8.9% 0.01% $5,056,200
NORTHERN TRUST CORP 0.89% 1,848,437 +3.6% 0% $4,898,358
GOLDMAN SACHS GROUP INC 0.82% 1,708,807 +114% 0% $4,528,339
CITADEL ADVISORS LLC 0.74% 1,530,364 -34% 0% $4,055,465
Integral Health Asset Management, LLC 0.72% 1,500,000 0.29% $3,975,000
UBS Group AG 0.6% 1,246,310 -19% 0% $3,302,722
MILLENNIUM MANAGEMENT LLC 0.47% 974,856 +115% 0% $2,583,368
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.46% 954,449 +14% 0% $2,529,290
JPMORGAN CHASE & CO 0.46% 945,491 +68% 0% $2,505,552
ROYAL BANK OF CANADA 0.44% 909,232 -22% 0% $2,410,000
RENAISSANCE TECHNOLOGIES LLC 0.37% 773,900 +165% 0% $2,050,835

Institutional Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 336,689 $1,246,628 +$158,628 $3.70 17
2025 Q3 108,004,285 $286,206,908 +$32,005,545 $2.65 188
2025 Q2 98,221,986 $96,659,560 -$21,194,525 $0.98 161
2025 Q1 111,244,473 $160,207,390 -$24,300,645 $1.44 183
2024 Q4 126,046,299 $277,285,420 +$4,393,183 $2.20 188
2024 Q3 128,986,677 $212,839,069 -$18,982,245 $1.65 181
2024 Q2 136,753,565 $303,582,298 +$17,706,459 $2.22 173
2024 Q1 125,253,343 $335,669,495 +$141,351,114 $2.68 147
2023 Q4 71,634,221 $214,185,830 -$13,154,422 $2.99 127
2023 Q3 77,232,361 $75,678,982 -$1,733,880 $0.98 120
2023 Q2 74,286,796 $103,280,736 -$10,483,186 $1.39 121
2023 Q1 80,929,285 $128,750,548 -$22,081,506 $1.59 161
2022 Q4 73,478,005 $457,748,937 +$39,215,603 $6.23 164
2022 Q3 62,444,882 $418,381,560 +$53,328,619 $6.70 143
2022 Q2 55,366,705 $352,132,262 +$24,287,037 $6.36 128
2022 Q1 51,922,058 $241,219,302 -$10,656,706 $4.64 121
2021 Q4 53,613,124 $268,022,905 +$97,310,967 $5.00 119
2021 Q3 24,797,305 $298,815,522 -$61,530,602 $12.05 133
2021 Q2 28,340,478 $599,385,890 -$18,947,335 $21.15 140
2021 Q1 28,702,213 $805,059,737 -$64,474,348 $28.05 151
2020 Q4 30,878,165 $802,895,778 -$34,208,444 $26.00 152
2020 Q3 31,640,175 $1,176,015,102 -$28,756,691 $37.17 165
2020 Q2 31,971,491 $1,640,380,010 +$123,898,647 $51.31 179
2020 Q1 29,570,957 $916,082,618 +$53,953,340 $31.53 157
2019 Q4 27,848,044 $1,621,473,992 +$45,891,970 $59.63 170
2019 Q3 27,027,940 $990,522,973 -$72,172,854 $36.66 145
2019 Q2 28,447,747 $1,323,221,426 +$216,701,139 $46.52 166
2019 Q1 27,588,882 $1,107,641,121 +$27,039,632 $40.15 160
2018 Q4 26,812,324 $1,233,297,022 -$65,824,574 $46.00 152
2018 Q3 28,254,155 $1,253,898,089 -$106,658,510 $44.37 151
2018 Q2 30,817,874 $1,207,760,885 +$133,006,694 $39.19 151
2018 Q1 26,467,526 $1,914,388,196 +$178,186,545 $72.33 184
2017 Q4 24,011,278 $1,580,908,389 +$28,478,384 $65.84 163
2017 Q3 24,158,062 $1,210,838,699 +$158,389,093 $50.12 150
2017 Q2 20,787,063 $962,036,441 +$142,703,625 $46.28 129
2017 Q1 17,982,623 $634,962,044 +$201,687,554 $35.31 116
2016 Q4 14,790,757 $185,178,042 +$1,997,113 $12.52 96
2016 Q3 14,434,779 $199,910,330 -$703,426 $13.85 98
2016 Q2 14,667,103 $144,916,054 -$27,764,688 $9.88 98
2016 Q1 15,788,626 $266,644,000 -$13,544,152 $16.91 104
2015 Q4 16,427,090 $365,743,034 -$11,898,095 $22.26 111
2015 Q3 16,611,937 $391,855,349 -$215,978,223 $23.59 120
2015 Q2 15,304,049 $1,251,247,346 +$182,794,461 $81.76 150
2015 Q1 12,803,656 $1,185,461,048 +$474,650,240 $92.60 139
2014 Q4 7,779,336 $314,790,098 +$168,789,584 $40.44 82
2014 Q3 3,501,400 $85,642,436 +$3,067,413 $24.46 49
2014 Q2 5,556,294 $88,004,478 +$33,701,269 $15.84 43
2014 Q1 3,430,835 $51,872,345 +$961,180 $15.12 40